Skip to content

Efficacy of Albumin Platelet Rich Fibrin on Complications After Mandibular Third Molar Extraction.

Efficacy of Albumin Platelet Rich Fibrin on Complications After Mandibular Third Molar Extraction: A Clinical and Biochemical Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07153133
Enrollment
16
Registered
2025-09-03
Start date
2025-09-20
Completion date
2026-03-01
Last updated
2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tooth Extraction Site Healing

Brief summary

Sixteen patients with bilateral impacted lower third molars seeking treatment will be recruited from the out-patient clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry at Mansoura University.

Interventions

DEVICEAlb-PRF Autologous Albumin Gel

Socket curettage and bone filing will be done using a bone curette and bone file, respectively. Extraction sockets with albumin gel application. 0.2 ml of autologous albumin gel will be applied to all four edges of the extraction socket

Socket curettage and bone filing will be done using a bone curette and bone file, respectively. Extraction sockets will be left without autologous albumin gel application.

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Healthy patients classified as ASA (American Society of Anesthesiologists) Physical Status Classification Class I. * Patients seeking extraction of both mandibular third molars. * Patients aged 18 - 40 years old by the day of surgery. * Patients willing to participate in the study and commit to regular follow-up appointments.

Exclusion criteria

* Heavy Smokers (more than 25 cigarettes per day). * Patients with Poor oral hygiene. * Patients with history of a chemotherapy or radiotherapy

Design outcomes

Primary

MeasureTime frameDescription
Assessment of Facial Swelling (Edema): in Centimetersfirst day, third day and seventh dayMeasurements will be taken before surgery (baseline). Swelling will be evaluated by comparing the difference between preoperative and postoperative measurements. Swelling will be evaluated in Centimeters using a tape measure. Performed on the patient's operated site using these reference points: * A) Lateral corner of the eye/angle of the mandible * B) Tragus/outer corner of the mouth * C) Tragus/soft tissue pogonion
Wound Healing: Disturbed/Not Disturbedfirst day, third day and seventh dayThe area of operation will be examined for Any manifestations of wound healing disturbance including: * Swelling, redness, hotness, pus discharge, signs and symptoms of infection, Wound dehiscence * Exposure of underlying hard tissue will be carefully noted
Postoperative pain severity assessment : using a 10 point Visual Analogue Scale (VAS)first day, third day and seventh dayPain will be evaluated using Visual Analogue Scale (VAS). Which is a 10 point scale, in which the minimum end '0" represents no pain, while the maximum end 10" represents the worst pain.
Laboratory Assessments of multiple blood/Biochemical markers and their concentrationsfirst day, third day and seventh dayFirst 5 cm of blood will be withdrawn under aseptic conditions using sterile venipuncture, then blood will be separated immediately by centrifugation (3000 rpm). To be assessed using enzyme-linked immunosorbent assays (ELISA) kits according to the manufacturer's protocol for their Serum concentrations of: interleukin 6, macrophage inflammatory protein, granulocyte macrophage colony-stimulation factor, and vascular endothelial growth factor

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026